Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis

Lee, Yong Sang; Seo, Yeon Seok; Shin, In-Soo; Yoon, Won Sup; Lee, Hye Yoon; Rim, Chai Hong

doi:10.1016/j.ijsu.2022.106753

Cited by 3 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, liver tumors, as well as tumors arising from the bone marrow and lymphatic tissue, are highly sensitive to radiation treatment. , Therefore, stereotactic body radiotherapy (SBRT) has been recommended as a primary treatment modality for early liver cancer. , Radiotherapy is often combined with transcatheter arterial chemoembolization (TACE) to treat more advanced HCC. , However, the local control achieved following radiotherapy is still inferior, with about 90% of the irradiated HCC recurring within the radiation field or at a distant site . Locoregional recurrence and intrahepatic or extrahepatic metastasis remain the main cause of cancer-related death in HCC patients treated with radiotherapy . Therefore, there is a need to develop effective treatment strategies to improve the radiosensitivity of HCC and, thus, improve local control following radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BMI1 Silencing Liposomes Suppress Postradiotherapy Cancer Stemness against Radioresistant Hepatocellular Carcinoma

Zhu,

Fan,

Deng

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…10 Locoregional recurrence and intrahepatic or extrahepatic metastasis remain the main cause of cancer-related death in HCC patients treated with radiotherapy. 11 Therefore, there is a need to develop effective treatment strategies to improve the radiosensitivity of HCC and, thus, improve local control following radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

BMI1 Silencing Liposomes Suppress Postradiotherapy Cancer Stemness against Radioresistant Hepatocellular Carcinoma

Zhu,

Fan,

Deng

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis

Wang

Sun

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Benefit of perioperative radiotherapy for hepatocellular carcinoma: a quality-based systematic review and meta-analysis

Rim,

Park,

Yoon

2023

International Journal of Surgery

View full text Add to dashboard Cite

Introduction: Although surgery is the standard curative modality for hepatocellular carcinoma, more than two-thirds experience intrahepatic recurrence. Since no standard perioperative treatment has been established, we performed a meta-analysis to evaluate the benefits of perioperative radiotherapy (RT). Methods: The PubMed, MEDLINE, EMBASE, and Cochrane Library were searched until May 2023. Randomized or propensity-matched studies evaluating at least five major clinical factors investigating benefit of perioperative RT, were included. The main effect measure were the pooled odds ratios (OR) regarding the benefit of perioperative RT using 2-year overall survival (OS) and 1-year disease-free survival (DFS) data. Results: Seven studies (5 randomized and 2 propensity-matched studies) involving 815 patients were included. The pooled ORs for 1-year DFS and 2-year OS were 0.359 (95% confidence interval [CI]: 0.246–0.523) and 0.371 (95% CI: 0.293–0.576), respectively, favoring perioperative RT, with very low heterogeneity. In the subgroup analyses, the benefits of OS and DFS were consistent between the two subgroups (portal vein thrombosis [PVT] and narrow resection margin [RM] groups). In the PVT subgroup, the pooled OS rates at both 1- and 2-year (75.6% vs. 36.9%, P<0.001; 25.6% vs. 9.9%, P=0.004) and DFS rates at both 1- and 2-year (25.2% vs. 10.3%, P=0.194; 11.9% vs. 3.0%, P=0.022) were higher in the perioperative RT group. In the narrow RM subgroup, the surgery and RT groups showed higher pooled OS rates for both 1- and 2-year (97.3% vs. 91.9%, P=0.042; 90.4% vs. 78.7%, P=0.051) and DFS (88.1% vs. 72.6%, P<0.001; 70.1% vs. 51.7%, P<0.001). Grade 5 toxicity was not reported, and three studies reported grade ≥3 or higher liver function test abnormalities, ranging from 4.8–19.2%. Conclusion: The present study supports the oncological benefits of perioperative RT, for cases with high risk of recurrence. Oncologic outcomes between subgroups differed according to clinical indications.

show abstract

Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis

Cited by 3 publications

References 80 publications

BMI1 Silencing Liposomes Suppress Postradiotherapy Cancer Stemness against Radioresistant Hepatocellular Carcinoma

BMI1 Silencing Liposomes Suppress Postradiotherapy Cancer Stemness against Radioresistant Hepatocellular Carcinoma

Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis

Benefit of perioperative radiotherapy for hepatocellular carcinoma: a quality-based systematic review and meta-analysis

Contact Info

Product

Resources

About